Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study

Abstract

These data indicate that a 3 day treatment with ciprofloxacin is at least as clinically and bacteriologically effective as 7 day treatments with trimethoprim/sulfamethoxazole and norfloxacin for uncomplicated lower urinary tract infections.

Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results

“…Our results confirm inferior bacterial clearance of 5-nitrofuran derivatives as after 5 days (median) only 10 of 14 patients had negative cultures. In contrast, most studies performed with co-trimoxazole and fluoroquinolones showed that maximal antimicrobial efficacy is observed as early as 3 days after initiation of treatment [16,21]. We achieved consistent results showing that after 4 days (median) no culture of ciprofloxacin-treated patients was positive.…”

Preparation andin vitro,in vivoevaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery

“…Furthermore, repeated administrations are required to attain a steady-state level of drug. The common usage of NFX is twice a day for 7 to 10 days or even longer for uncomplicated lower urinary tract infections leading to a frequent dosage (Arredondo et al, 2004). Prophylactic NFX to patients with cancer who were neutropenic or likely to develop cytotoxic therapy-induced neutropenia or gastrointestinal hemorrhage are given orally 400 mg twice daily lasting more than 7 days (Fernández et al, 2006;Carratala et al, 1998).…”

Urinary Tract Infections

“…TMP-SMX (1 double-strength tablet [160/800 mg] twice daily for 3 days): TMP-SMX has shown early clinical efficacy rate with a 3-day to 7-day regimen of 86% to 100% based on randomized trials, although more recent studies show higher resistance. [60][61][62][63][64] However, the conclusion from a more recent study notes that TMP-SMX may no longer be acceptable for the treatment of acute uncomplicated cystitis in the United States because of high resistance rates greater than 20% in many regions. 65 Although there is some debate on the use of empirical TMP-SMX for acute cystitis, it should be avoided as empirical treatment if the prevalence of resistance is known to be high in the area or if the patient has taken TMP-SMX for cystitis in the preceding 3 months.…”